Table 1.
list of clinical trials evaluating mRNA vaccines against infectious diseases.
| Application | Designation (Sponsor) | NCT number | Development phase | Date | Status |
|---|---|---|---|---|---|
| Influenza | mRNA NA vaccine (Sanofi Pasteur) | NCT05426174 | Phase 1 | 2022 | Active |
| GSK4382276A (GSK) | NCT05446740 | Phase 1 | 2022 | Recruiting | |
| mRNA-1010 (Moderna) | NCT04956575 | Phase 1/2 | 2021 | Completed | |
| NCT05415462 | Phase 3 | 2022 | Active | ||
| mRNA-1020 & 1030 (Moderna) | NCT05333289 | Phase 1/2 | 2022 | Completed | |
| MRT5407 (Sanofi Pasteur) | NCT05553301 | Phase 1 | 2022 | Recruiting | |
| Modified mRNA vaccine (Pfizer) | NCT05052697 | Phase 1/2 | 2022 | Recruiting | |
| Quadrivalent influenza modRNA vaccine (qIRV) (Pfizer) | NCT05540522 | Phase 3 | 2022 | Recruiting | |
| Quadrivalent Influenza mRNA Vaccine CVSQIV (CureVac) | NCT05252338 | Phase 1 | 20222 | Recruiting | |
| PF-07852352 & others Influenza saRNA (Pfizer) | NCT05227001 | Phase 1 | 2022 | Recruiting | |
| SARS-CoV-2 and Influenza | mRNA-1073 (Moderna) | NCT05375838 | Phase 1/2 | 2022 | Active |
| HIV | eOD-GT8 60mer (mRNA-1644) (IAVI, Moderna) | NCT05414786 | Phase 1 | 2022 | Active |
| mRNA-1644 & 1644v2-core (IAVI, Moderna) | NCT05001373 | Phase 1 | 2021 | Active | |
| BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines | NCT05217641 | Phase 1 | 2022 | Active | |
| Zika | mRNA-1325 (Moderna) | NCT03014089 | Phase 1 | 2017-2019 | Completed |
| mRNA-1893 (Moderna) | NCT04917861 | Phase 2 | 2021 | Active | |
| NCT04064905 | Phase 1 | 2019-2021 | Completed | ||
| CMV | mRNA-1647 (Moderna) | NCT05085366 | Phase 3 | 2021 | Recruiting |
| NCT05105048 | Phase 1 | 2021 | Recruiting | ||
| NCT04975893 | Phase 2 | 2021 | Enrolling by invitation | ||
| NCT04232280 | Phase 2 | 2020 | Active | ||
| NCT03382405 | Phase 1 | 2017-2021 | Completed | ||
| EBV | mRNA-1189 (Moderna) | NCT05164094 | Phase 1 | 2021 | Recruiting |
| RSV | mRNA-1345 (Moderna) | NCT05127434 | Phase 2/3 | 2021 | Recruiting |
| NCT05330975 | Phase 3 | 2022 | Recruiting | ||
| NCT04528719 | Phase 1 | 2020 | Active | ||
| hMPV, PIV3 | mRNA-1653 (Moderna) | NCT03392389 | Phase 1 | 2018-2020 | Completed |
| NCT04144348 | Phase 1b | 2019 | Active | ||
| Rabies | CV7201 (Curevac) | NCT02241135 | Phase 1 | 2014-2018 | Completed |
| CV7202 (CureVac) | NCT03713086 | Phase 1 | 2018-2021 | Completed | |
| HSV | BNT163 (BioNTech) | NCT05432583 | Phase 1 | 2022 | Recruiting |
| TB | BNT164a1 & BNT164 (BioNtech) | NCT05547464 | Phase 1 | 2022 | Not yet recruiting |
| NCT05537038 | Phase 1a | 2022 | Not yet recruiting | ||
| Nipah virus | mRNA-1215 (Moderna) | NCT05398796 | Phase 1 | 2022 | Recruiting |
| Chikungunya virus | mRNA-1944 (Moderna) | NCT03829384 | Phase 1 | 2019-2021 | Completed |
| Malaria | BNT165b1 (BioNtech) | NCT05581641 | Phase 1 | 2022 | Recruiting |